NASDAQ · IART

Integra LifeSciences Holdings

$19.53 -$0.26 (-1.31%) 1D After hours

Key Metrics

$1.54B
Market cap
P/E · TTM
$1.64B
Revenue · TTM
−$495.80M
Net income
EPS · TTM $-6.48
Dividend yield
Free cash flow $4.08M
Beta · 1Y 1.94
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 4
    The stock moved +9.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 4
  • May 5
    The stock moved +24.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 5
  • Mar 18
    From its Feb 20 high, the share price fell 27%.

    Peak close $12.21 on Feb 20; trough close $8.90 on Mar 18. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -27%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.54B
Enterprise value$1.99B
Shares outstanding77.8M
52-wk range$8.70 – $20.40
Avg volume · 20D723.3K
Net cash −$451.37M
Book value / share$13.63
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Integra LifeSciences Holdings
IPO dateAug 16, 1995
Employees4427

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.94
P/FCF377.35
EV/EBITDA
EV/Sales1.21
Graham №

Profitability

Gross
Operating -32.6%
Net -30.1%
FCF 0.2%
ROE / ROIC -38.3% · -33.2%

Financial Health

Current ratio3.38
Quick ratio1.95
Debt / equity0.69
Debt / EBITDA
Net cash −$451.37M
Working capital$825.17M

Cash Flow · TTM

Operating CF $71.44M
Capex −$67.36M
Free cash flow $4.08M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

0.8
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings